APGE
Apogee Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$135.07
+0.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -14.2%
- EBIT
- -21.2%
- EPS
- -4.3%
- Free cash flow
- -7.7%
- Operating cash flow
- -10.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -13.3%
Three-year CAGR
- Revenue
- —
- EBITDA
- -39.7%
- EBIT
- -31.7%
- Net income
- -40.5%
- EPS
- -27.9%
- Free cash flow
- -35.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026